MedTrace Logo

Sympathetic Mapping/ Ablation of Renal Nerves Trial - Hemodialysis

NCT04872114 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-05-04

No results posted yet for this study

Summary

To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I™ in patients on hemodialysis with pharmacotherapy and uncontrolled hypertension for at least 6 months, then after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days, office systolic blood pressure (BP) is still ≥ 150mmHg, ≤180mmHg.

Conditions

Interventions

DEVICE

SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator

Radiofrequency ablation of renal arterial sympathetic nerves

Sponsors & Collaborators

  • SyMap Medical (Suzhou), Ltd.

    collaborator INDUSTRY

  • The Second Hospital of Nanjing Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-05-01
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04872114 on ClinicalTrials.gov